Literature DB >> 7497161

A case-control study to evaluate efficacy of screening for faecal occult blood.

D Lazovich1, N S Weiss, N G Stevens, E White, B McKnight, E H Wagner.   

Abstract

OBJECTIVES: Faecal occult blood testing is routinely used for early detection of colorectal cancer, but evidence of its efficacy in preventing death from colorectal cancer is limited. A case-control study was carried out to evaluate whether screening for faecal occult blood is associated with a reduced risk of fatal colorectal cancer.
SETTING: A health maintenance organisation in western Washington State, which has offered its members faecal occult blood testing every two years since 1983.
METHODS: Cases (n = 248) were members of the health maintenance organisation who died from colorectal cancer between 1986 and 1991. For each case, two control subjects, who did not die from colorectal cancer and who were similar to each case in age, gender, and year of enrollment at the health maintenance organisation, were randomly selected from the membership list of the year in which the case was diagnosed (n = 496). Information about episodes of faecal occult blood testing (including the location and reason for the test, and the evaluation of positive tests) and potential confounders was obtained from medical records.
RESULTS: Cases were less likely than controls to have ever been screened (odds ratio (OR) = 0.7, 95% confidence interval (CI) 0.5 to 1.0), consistent with a beneficial impact of screening. There was little difference, however, for screening that had taken place within a three year period before diagnosis (OR = 0.9, 95% CI 0.6 to 1.2), the maximum interval during which most tumours ought to have been detectable by faecal occult blood testing. A reduction in risk was seen for home testing but not for office testing, and in individuals aged less than 75 but not in those aged 75 or older. Although most of the 21 controls with a positive faecal occult blood test underwent some additional testing, only five (24%) were evaluated with colonoscopy or air contrast barium enema.
CONCLUSIONS: While there can be uncertainty as to whether specific faecal occult blood tests were performed as screening or diagnostic tests, those performed at home and in younger persons may be relatively less likely to be diagnostic tests that were misclassified as screening. Thus the modest reduced risk associated with faecal occult blood testing in these settings/persons may reflect genuine benefit. However, the presence of a reduced risk associated with a screening faecal occult blood test received in the past, well before a tumour or polyp might bleed enough to allow detection, is compatible with uncontrolled confounding. Interpretation is further complicated by the fact that a number of individuals in the study group who had positive test results underwent limited or no diagnostic testing. Thus our results should be interpreted with considerable caution.

Entities:  

Mesh:

Year:  1995        PMID: 7497161     DOI: 10.1177/096914139500200206

Source DB:  PubMed          Journal:  J Med Screen        ISSN: 0969-1413            Impact factor:   2.136


  8 in total

1.  Computed tomography colonography (virtual colonoscopy): a new method for colorectal screening.

Authors:  C D Johnson; D A Ahlquist
Journal:  Gut       Date:  1999-03       Impact factor: 23.059

2.  Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial.

Authors:  J H Scholefield; S Moss; F Sufi; C M Mangham; J D Hardcastle
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

Review 3.  Antagonist: population based endoscopic screening for colorectal cancer.

Authors:  D A L Macafee; J H Scholefield
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

Review 4.  Screening for colorectal cancer using the faecal occult blood test, Hemoccult.

Authors:  P Hewitson; P Glasziou; L Irwig; B Towler; E Watson
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

Review 5.  The impact of screening on colorectal cancer mortality and incidence: has it really made a difference?

Authors:  Ann G Zauber
Journal:  Dig Dis Sci       Date:  2015-03-05       Impact factor: 3.199

6.  The risks of screening: data from the Nottingham randomised controlled trial of faecal occult blood screening for colorectal cancer.

Authors:  M H Robinson; J D Hardcastle; S M Moss; S S Amar; J O Chamberlain; N C Armitage; J H Scholefield; C M Mangham
Journal:  Gut       Date:  1999-10       Impact factor: 23.059

7.  Immunochemical vs guaiac faecal occult blood tests in a population-based screening programme for colorectal cancer.

Authors:  G Castiglione; M Zappa; G Grazzini; A Mazzotta; M Biagini; P Salvadori; S Ciatto
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

8.  The IARC Perspective on Colorectal Cancer Screening.

Authors:  Béatrice Lauby-Secretan; Nadia Vilahur; Franca Bianchini; Neela Guha; Kurt Straif
Journal:  N Engl J Med       Date:  2018-03-26       Impact factor: 176.079

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.